Patient experience is among the most powerful, yet most overlooked indicators defining a healthcare system’s financial, reputational and operational resilience. More than a soft metric, positive experiences translate to stronger revenue performance — and that correlation becomes especially evident in upper respiratory infection (URI) diagnostics.
Traditional nasopharyngeal swabs remain the default sampling method after COVID-19, but memories of an intrusive, painful process now lead many people to postpone testing or avoid it altogether. And even if they seek early care, nasal swabs are prone to inconsistent specimen quality leading to inconclusive results, poor health outcomes and costly consequences.
A shift toward swab-free specimen collection with evolved nasal lavage gives patients an option they don’t dread. This method gently flushes the nasopharyngeal cavity with saline rather than ramming it with a swab to virtually eliminate pain while collecting higher-sensitivity samples.
When testing feels more like a quick refreshing rinse than an irritating invasive probe, patients feel at ease, providers work smarter, labs make sharper decisions — and the ripple effect boosts revenue systemwide.
Comfort Boosts Patient Satisfaction Rates & Bottom Lines
URIs spur heavy volumes of inpatient visits, and getting tested is often the most memorable, and in most cases unpleasant, part of those encounters. When deep nasal swabbing makes that step painful, it reflects poorly on the entire facility; even if the care delivery itself was outstanding.
That sentiment can translate into negative comments in online surveys and reviews, which harm a facility’s public perception and its ability to secure new patients. And when tied to scoring for Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS), the operational impact is often even more direct.
Hospitals with “excellent” HCAHPS patient ratings have average net margins of 4.7% compared with 1.8% among those with low ratings, according to Deloitte — showing that better patient-reported scores directly correlate with higher profitability.
Value-based purchasing programs also tie a portion of reimbursement directly to HCAHPS performance, meaning lower satisfaction can lead to penalties as higher satisfaction protects and enhances revenue.
Evolved sampling methods that prioritize comfort can strengthen patient experiences as well as systemwide bottom lines because:
- Patients are more willing to get tested early in their illness instead of delaying or avoiding care due to anxiety surrounding the swab.
- Families perceive visits as more considerate and child-friendly, thanks to gentler testing.
- High-volume testing sites accumulate better experiential data over time, and a pain-free sampling process helps ensure this data skews positive.
Organizations that prioritize comfort tend to win financially, supporting clinical goals as well as the healthcare system’s reputation.
Happier Patients Ease Provider Burnout & Save Time
Roughly half of U.S. physicians report at least one symptom of burnout — nearly twice the rate of the general working population — which costs our healthcare system an estimated $4.6 billion annually from turnover and presenteeism, according to the Annals of Internal Medicine.
Heightened burnout is tied to lower productivity, more errors, higher costs and compromised safety. And URI sampling, specifically, is a common staff stressor:
- Patients flinch, gag, cough or pull away during nasal swab sampling, hindering the process while reducing sample adequacy.
- Staff must repeat instructions, reposition swabs and sometimes start over.
- Providers lean in close to the patient’s face, increasing their own exposure risk.
- Occasional swab-related complications, such as retained fragments or epistaxis, require extra clinical attention and fuel concerns of liability risk.
Evolved nasal lavage methods paired with PCR flips the script with a gentle saline wash that brings less variability and more peace of mind. When sampling feels quick and tolerable, clinicians can smoothly move through each visit without bracing for a tug-of-war over the swab and the patient may even thank them for the refreshing rinse.
This standardized, pain-free alternative reduces emotional load on staff while obtaining a high-quality specimen on the first attempt. That means fewer mishaps and misdiagnoses that consequently take up valuable space, time and resources.
High-Sensitivity Sampling Supports Stronger Economics
The quality of a respiratory specimen determines efficiency throughout the trajectory of care — which ultimately determines an organization’s financial performance.
With swabs, insertion depth depends on how much discomfort a patient can tolerate, often barely reaching past the mid-nasal passage. This leads to shallow, low-yield specimens and a higher chance of false negatives. When early results miss the mark, treatments are delayed and often misguided, and illnesses have more room to progress.
Those gaps drive predictable strain: repeat visits for unresolved symptoms, secondary infections like bacterial pneumonia, extended recovery timelines and higher viral transmission. Each outcome drains resources that could have been preserved with an initially accurate diagnosis:
- Avoidable ED revisits for treatable conditions including respiratory issues cost U.S. health systems an average $32 billion per year, according to United Health Group.
- Springer Nature reports inpatient stays linked to complications like pneumonia cost hospitals $10,000 to $20,000 per admission, with severe cases being even more costly.
- Extended length of stay magnifies labor and bed-capacity pressures, particularly during peak respiratory season when every staffed bed carries opportunity cost.
High-sensitivity options like evolved nasal lavage interrupt that cycle early, capturing a more representative sample to minimize false negative PCR tests. Clinicians can then initiate targeted treatment earlier, minimize unscheduled repeat visits, and eliminate the need for hospitalization.
The downstream effect? Fewer dollars lost to preventable escalations in care.
Ramp Up Systemwide Efficiency & Cost Savings with MicroWash
Healthcare leaders ready to operationalize these gains need solutions that are not only clinically superior to the nasal swab, but also standardized, reimbursable and easy to adopt at scale.
MicroWash is the first nasal lavage specimen collection device for URI testing that pairs a comfortable patient experience with up to 49% greater sample sensitivity compared to swabs. The compact device gently flushes the nasal cavity and is far less intrusive: Patient pain ratings average just 0.3/10 compared to the nasal swab at 8 out of 10.
For providers and labs, MicroWash delivers high-sensitivity specimens to support accurate, early diagnoses while eliminating extraction errors and fitting smoothly into established PCR workflows.
Capturing better samples through a pain-free process helps improve testing volumes, patient satisfaction, diagnostic confidence and overall public health outcomes to strengthen both care quality and financial outlooks.
Contact the experts behind MicroWash to align your sampling strategy with the economic resilience your system needs to thrive in the next respiratory season and beyond.
